Skip to content
Sign in

ACAD · NASDAQ

ACADIA Pharmaceuticals (ACAD) Stock Price & Fundamentals

$811.04+0.98%+$7.90End-of-day price as of Oct 9, 2026

ACADIA Pharmaceuticals (ACAD) closed at $811.04 on Oct 9, 2026, up 0.98% from the previous close of $803.14.

Share price, past year

1Y +27.55%

52-week range $632.28 – $818.75. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$811.04
Sep 30, 2026$798.42
Aug 31, 2026$764.89
Jul 31, 2026$722.10
Jun 30, 2026$739.01
May 29, 2026$728.05
Apr 30, 2026$733.41
Mar 31, 2026$677.93
Feb 27, 2026$704.90
Jan 30, 2026$647.97
Dec 31, 2025$659.56
Nov 28, 2025$669.94
Oct 31, 2025$632.28

Key statistics

Market cap
$139.61B
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
$1.14B
Net income (TTM)
$380.48M
Shares outstanding
172.1M
Dividend yield
—
52-week range
$632.28 – $818.75

ACADIA Pharmaceuticals's market cap is $139.61B, based on a share price of $811.04 and 172.1M shares outstanding as of Jun 30, 2026.

Financials

ACADIA Pharmaceuticals reported revenue of $1.07B for fiscal 2025, up 11.87% from fiscal 2024.

ACADIA Pharmaceuticals earned net income of $391.00M in fiscal 2025, a net margin of 36.5%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
ACADIA Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$1.07B+11.9%$391.00M36.5%$2.30$105.15M
FY2024ended Dec 31, 2024$957.80M+31.9%$226.45M23.6%$1.36$157.20M
FY2023ended Dec 31, 2023$726.44M+40.5%−$61.29M−8.4%−$0.37$16.65M
FY2022ended Dec 31, 2022$517.24M+6.8%−$215.98M−41.8%−$1.34−$114.04M
FY2021ended Dec 31, 2021$484.15M+9.6%−$167.87M−34.7%−$1.05−$126.78M
FY2020ended Dec 31, 2020$441.76M+30.3%−$281.58M−63.7%−$1.79−$143.75M
FY2019ended Dec 31, 2019$339.08M+51.5%−$235.26M−69.4%—−$152.26M
FY2018ended Dec 31, 2018$223.81M+79.2%−$245.19M−109.6%—−$169.57M
FY2017ended Dec 31, 2017$124.90M+620.7%−$289.40M−231.7%—−$218.57M
FY2016ended Dec 31, 2016$17.33M—−$271.39M−1,565.9%—−$209.91M
ACADIA Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$307.96M$31.50M$0.18
Q1 FY2026ended Mar 31, 2026$268.06M$3.64M$0.02
Q4 FY2025ended Dec 31, 2025$283.99M$273.57M—
Q3 FY2025ended Sep 30, 2025$278.63M$71.78M$0.42
Q2 FY2025ended Jun 30, 2025$264.57M$26.67M$0.16
Q1 FY2025ended Mar 31, 2025$244.32M$18.99M$0.11
Q4 FY2024ended Dec 31, 2024$259.60M$143.74M—
Q3 FY2024ended Sep 30, 2024$250.40M$32.77M$0.20

Company profile

Name
ACADIA Pharmaceuticals Inc.
Ticker
ACAD
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
12830 El Camino Real, Suite 400, San Diego, CA 92130
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001070494

Recent SEC filings

Frequently asked questions

What is ACADIA Pharmaceuticals's stock price?

ACADIA Pharmaceuticals (ACAD) closed at $811.04 on Oct 9, 2026, up 0.98% from the previous close of $803.14.

What is ACADIA Pharmaceuticals's market cap?

ACADIA Pharmaceuticals's market cap is $139.61B, based on a share price of $811.04 and 172.1M shares outstanding as of Jun 30, 2026.

How much revenue does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals reported revenue of $1.07B for fiscal 2025, up 11.87% from fiscal 2024.

Does ACADIA Pharmaceuticals pay a dividend?

ACADIA Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from ACADIA Pharmaceuticals Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures